NasVax: Closing Share Purchase Agreement of Protea Vaccine Technologies
Protea has become a fully owned subsidiary of NasVax
14-Jul-2009 -
NasVax Ltd. announced that it has closed the purchase of 100% of the shares of Protea Vaccine Technologies of Kiryat Shmona Israel. As a result, Protea has become a fully owned subsidiary of NasVax.
In June 2009, Protea announced that it signed a Research and License Option Agreement with ...
diseases
GlaxoSmithKline
proteins
+1